
Afuresertib hydrochloride
CAS No. 1047645-82-8
Afuresertib hydrochloride ( GSK 2110183 hydrochloride | GSK2110183 hydrochloride )
产品货号. M10235 CAS No. 1047645-82-8
一种有效的、选择性的 ATP 竞争性泛 AKT 抑制剂,对于 AKT1/2/3 的生化 IC50 为 0.08/2/2.6 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥356 | 有现货 |
![]() ![]() |
5MG | ¥551 | 有现货 |
![]() ![]() |
10MG | ¥778 | 有现货 |
![]() ![]() |
25MG | ¥1345 | 有现货 |
![]() ![]() |
50MG | ¥2155 | 有现货 |
![]() ![]() |
100MG | ¥3726 | 有现货 |
![]() ![]() |
200MG | ¥4844 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Afuresertib hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的、选择性的 ATP 竞争性泛 AKT 抑制剂,对于 AKT1/2/3 的生化 IC50 为 0.08/2/2.6 nM。
-
产品描述A potent, selective, ATP-competitive pan-AKT inhibitor with biochemical IC50 of 0.08/2/2.6 nM for AKT1/2/3; also inhibits PKA (IC50=1.3 nM) and AKT1 E17K mutant (IC50=0.2 nM), selective over PKC, PKG isoforms and p70S6K; orally bioactive.Gastric Cancer Phase 1 Discontinued(In Vitro):Afuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase.Western blotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response. (In Vivo):Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
-
体外实验Afuresertib (GSK 2110183) exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G1 phase. Western blotting analysis shows that Afuresertib increases the expression of p21WAF1/CIP1 and decreases the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression E2F1 and MYC, which are associated with fibroblast core serum response.
-
体内实验Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183 well, with 1-3% body weight loss reported after 5 days of dosing which recover over the course of the study. Other tumor xenograft models which possess an activation of the Akt pathway are explored to further demonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
-
同义词GSK 2110183 hydrochloride | GSK2110183 hydrochloride
-
通路PI3K/Akt/mTOR signaling
-
靶点Akt
-
受体Akt
-
研究领域Cancer
-
适应症Gastric Cancer
化学信息
-
CAS Number1047645-82-8
-
分子量463.7841
-
分子式C18H18Cl3FN4OS
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 52 mg/mL
-
SMILESCN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl.Cl
-
化学全称2-Thiophenecarboxamide, N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Dumble M, et al. PLoS One. 2014 Jun 30;9(6):e100880.
2. Spencer A, et al. Blood. 2014 Oct 2;124(14):2190-5.
3. Arceci RJ, et al. Pediatr Blood Cancer. 2017 May;64(5).
产品手册




关联产品
-
2,3-Butanedione 2-Mo...
Perifosine (KRX-0401; D-21266; NSC 639966) 是一种新型 Akt 抑制剂,IC50 为 4.7μM,靶向 Akt 的 pleckstrin 同源结构域。
-
PF-04691502
PF-04691502 是一种 ATP 竞争性 PI3K(α/β/δ/γ)/mTOR 双重抑制剂,Ki 为 1.8 nM/2.1 nM/1.6 nM/1.9 nM 和 16 nM。
-
Triciribine
Triciribine 是一种 DNA 合成抑制剂,还抑制 Akt 和 HIV-1,IC50 分别为 130 nM 和 20 nM。